PanTera signs a second agreement for the supply of actinium-225
14 Março 2024 - 3:00AM
PanTera signs a second agreement for the supply of actinium-225
PanTera’s continues to deploy its strategy
to become a market leader into the production and distribution of
Ac225
Mol, Belgium, March 14, 2024:
PanTera, the Belgian radioisotope producer created as a joint
venture by IBA and SCK CEN with the primary goal to secure
large-scale production of actinium-225 (225Ac), today announces the
signing of a strategic supply contract with an undisclosed partner.
This second supply agreement from PanTera underscores its
commitment to enabling the advancement of transformative cancer
treatments and reflects the growing demand for 225Ac in
cutting-edge clinical trials.
Under the terms of the agreement, PanTera will
provide 225Ac to its partner for at least the next 2 years, with
options for future prolongation. This important contract represents
15% to 20% of the yearly volumes PanTera will be producing based on
the thorium-229 (229Th) to be provided by TerraPower. Financial
terms of the contract are not disclosed.
This new agreement reflects PanTera’s unique
position as a reliable, long-term, EU-based supplier of 225Ac. Over
the next 5 years, the company will continue to work on securing and
increasing access to 225Ac for clinical trial needs, as well as the
construction of a large-scale, state-of-the-art production facility
to address the growing global demand.
Sven Van den Berghe, CEO of PanTera,
commented, “We welcome this second strategic supply
contract as a confirmation of our chosen strategy. Providing 225Ac
as from this year is extremely important to support the industry in
its development and qualification of these promising treatments in
the fight against cancer. In the meantime, PanTera is progressing
rapidly towards launching its large-scale production to meet the
anticipated significant global radioisotope demand increase once
targeted 225Ac-based therapeutics are approved in 4-5 years.”
225Ac is an alpha-emitter which, when attached
to a tumour-seeking vector, can deliver therapeutic doses of
radiation directly to tumours and metastases, destroying the cancer
cells while sparing the surrounding healthy tissue. It is
widely regarded as an isotope with tremendous potential in Targeted
Alpha Therapy (TAT) across a range of cancer types. Whilst there is
high demand for 225Ac for clinical trial today, there is already a
global supply shortage. PanTera was launched by IBA and SCK CEN in
2022 to address this supply issue both in the short and the long
term.
***
About PanTera
PanTera, an IBA and SCK CEN joint-venture, aims
to secure the large-scale production of actinium-225 (225Ac), one
of the most promising alpha-emitting radioisotopes to fight
cancers. By working towards this large-scale production, PanTera’s
ultimate goal is to improve the accessibility of future innovative
cancer therapy based on 225Ac and theranostics in general.
More information can be found at:
www.pantera-life.com
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 2,000 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found
at: www.iba-worldwide.com
About SCK CEN
70 years of experience in nuclear research and
technology
SCK CEN is one of the largest research
institutions in Belgium. Every day, more than 900 employees
dedicate themselves to developing peaceful applications of
radioactivity. SCK CEN's research activities focus on three main
areas: innovative nuclear systems, nuclear waste management and
dismantling, and the resolute fight against cancer. World-renowned,
SCK CEN shares its knowledge through countless publications and
training courses, so that this pool of exceptional competence can
be maintained.
More information can be found at:
www.sckcen.be
CONTACTS
PanTeraSven Van den Berghe–
info@pantera-life.com
IBA : Soumya Chandramouli
(Chief Financial Officer) – investorrelations@iba-group.comOlivier
Lechien (Corporate Communication Director) –
communication@iba-group.com+32 10 475 890
SCK CENWendy De Groote –
pers@sckcen.be+32 471 78 37 35
- 240314-PR-Pantera_SupplyAgreement2_EN
Ion Beam Applications (EU:IBAB)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Ion Beam Applications (EU:IBAB)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
